Elizabeth Jeffords, Chief Commercial and Strategy Officer and Eva Czirr, Associate Director, Alkahest talk about how they are applying their expertise in age-related and neurodegenerative and cognitive diseases to treating chronic kidney disease particularly end stage renal disease. With a focus on cognitive impairment related to inefficient dialysis, Alkahest is decoding the protein beta-2 microglobulin to determine if alleviation of a massive overload of the protein can benefit patients.
@alkahestinc #CKD #ESRD #B2M
Alkahest.com
Download the transcript here
Empowered Patient Podcast